Navigation Links
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
Date:6/8/2009

al," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Later this year we will complete Phase 1 testing of the IV dosage form of torezolid and plan to merge the oral and IV programs in Phase 3 testing early next year. Our aim is to make torezolid available to physicians and patients as soon as possible to address the growing unmet medical need for an effective and well tolerated new IV and oral treatment for drug-resistant infections."

About Torezolid (TR-701)

Torezolid is a second-generation IV/oral antibacterial drug in the oxazolidinone class. It is significantly differentiated from Zyvox(R) (linezolid), the only marketed drug in this class. Advantages of torezolid over linezolid include:

  • 4-8 fold greater potency than linezolid in vitro and in vivo
  • In vivo bactericidal activity
  • Activity against all clinically important, gram-positive, drug-resistant strains including those resistant to linezolid
  • Activity against clinically important atypical and gram-negative pathogens (Legionella, Chlamydia, Neisseria)
  • 16x lower rate of resistance development in MRSA
  • Once-daily and shorter course of therapy to promote better treatment compliance
  • Broader safety window enabling potential longer course of therapy
  • Possibility for expanded indications including bacteremia, severe CAP and osteomyelitis
  • Lower potential for drug-drug interactions including those with dietary tyramine, SSRIs and vasoconstrictors

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity agai
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
2. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
3. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
4. Trius Doses First Patient in Antibacterial Phase 2 Trial
5. PacificGMP Completes GMP Product Fill for Trius Therapeutics
6. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
7. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... BARCELONA , Spanje, July 4, 2015 ... SIR-Spheres® Y-90 harsmicrosferen aan eerstelijns chemotherapie voor ... de lever (mCRC) verlengt de progressievrije overleving ... met niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die ... grootste verbetering gezien in progressievrije overleving (PFS) ...
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... YORK , July 3, 2015  Obsidian HDS, ... - an online service for the management of data ... announced today that PharmaShine now includes the 2014 Open ... for Medicare Services on June 30. The data disclosed ... million transactions between industry and providers totaling $6.49 billion ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... 8, 2010 VIVUS, Inc. (Nasdaq: ... commercialization of novel therapeutic products, today reported its financial results ... 2010. Third Quarter HighlightsOn September 21, ... Qnexa which showed significant and sustained weight loss of greater ...
... 2010 Amgen (Nasdaq: AMGN ) today ... 3 study of 2,046 patients which compared denosumab with ... (SREs) in breast cancer patients with bone metastases. An ... fracture, the need for radiation or surgery to ameliorate ...
Cached Medicine Technology:VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 2VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 3VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 4VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 5VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 6Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 2Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 3Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 4Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 5Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 6Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 7Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 8Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer 9
(Date:7/3/2015)... ... 03, 2015 , ... First Choice Emergency Room , the largest network ... as the new Medical Director of its Frisco facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/3/2015)... ... 2015 , ... Every year, One-to-1 Fitness and the Red Deer Fit ... Red Deer community with free fitness training and indoor fitness boot camp classes for ... entertainment raised thousands of charity dollars and ended with a $10,000 donation to the ...
(Date:7/2/2015)... ... ... pleased to announce the opening of its newest location in Dallas, Texas. The opening is ... chain was listed as #22 on the Inc. 500 list of fastest growing companies in ... located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are excited ...
(Date:7/2/2015)... ... 2015 , ... The American Association of Poison Control Centers ... Stat (S.O.S.) Act of 2015 on June 23, 2015. Together with the Senate ... drug overdose – especially of heroin and opioid medication – by expanding the ...
(Date:7/2/2015)... ... ... summer in full swing, Americans are flocking to Canada’s many lakes to reel in their ... the world, and it’s easy to understand why. From the Pacific Northwest Coast of British ... fishing is a huge industry, and Americans make up the vast majority of anglers from ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... THURSDAY, April 14 (HealthDay News) -- Trying to make the best ... managers cope with losing their jobs, a new United Kingdom study ... coping with their job loss were able to see the event ... work, volunteering and study. They also took a contemplative view ...
... four years old when he went to sleep on his bunk ... strangled to death the next morning with his neck caught between ... Ryan is not the only child to have strangled in the ... incidents have been reported to the Consumer Product Safety Commission (CPSC). ...
... A team of Boston University researchers has found that ... having poor oral health. They also found that opioid ... over the period of one year. These findings appear ... Public health, dental medicine and internal medicine ...
... of Cincinnati (UC) shows that urban adolescents with asthma ... and often use complementary and alternative medicine, or integrative ... These findings, being presented at the National Conference ... physicians and other providers gain insight into additional ways ...
... , THURSDAY, April 14 (HealthDay News) -- The best ... new study suggests. Supportive reactions by managers and ... to positive changes in the workplace, while chastising or ... chair of the human resource management department at Temple ...
... April 14, 2011 An enzyme essential for DNA replication ... be exploited as anti-cancer therapy, say researchers at The Scripps ... published in the April 15, 2011 issue of the journal ... called flap endonucleases, which are essential to the life of ...
Cached Medicine News:Health News:Good Attitude Critical When Coping With Layoff Trauma 2Health News:Human Factors/Ergonomics research leads to improved bunk bed safety standards 2Health News:Integrative medicine, spirituality improves outcomes in urban adolescents with asthma 2Health News:Integrative medicine, spirituality improves outcomes in urban adolescents with asthma 3Health News:Integrative medicine, spirituality improves outcomes in urban adolescents with asthma 4Health News:Compassion, Not Punishment, Helps Diffuse Workplace Anger: Study 2Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 2Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 4
circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
The Secretion Solution., ,Available Configurations: , Straight Flex Tube, Poppel Flex Tube, MDI Adaptor ...
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
Medicine Products: